Shares of Aytu Biopharma Inc (NASDAQ:AYTU) rose sharply in pre-market trading after the pharmaceutical company reported its fiscal 2027 first-quarter results and announced a proposed acquisition by Rosemont Pharmaceuticals.
Aytu BioPharma faces a challenging outlook as its core ADHD and specialty portfolio struggles to maintain market share, evidenced by a revenue decline to $12.4M in 2026Q3 from $18.7M in 2024Q2.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 16, 2026 | -$0.20+22.1% vs -$0.26 | $15M+11.8% vs $13M |
Q4 2026 Sep 22, 2026 | -$0.05+82.8% vs -$0.29 | $16M+31.2% vs $12M |
Q2 2026 May 13, 2026 | -$0.53-71.0% vs -$0.31 | $12M+3.0% vs $12M |
Q1 2026 Feb 3, 2026 | -$1.05-303.8% vs -$0.26 | $15M+24.9% vs $12M |
Shares of Aytu Biopharma Inc (NASDAQ:AYTU) rose sharply in pre-market trading after the pharmaceutical company reported its fiscal 2027 first-quarter results and announced a proposed acquisition by Rosemont Pharmaceuticals.
Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.08 per share a year ago.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Aytu BioPharma, Inc. (NASDAQ: AYTU) to Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share.Halper Sadeh encourages Aytu shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whether Aytu and its board of directors vio.
GREENVILLE, S.C. and LEEDS, United Kingdom, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rosemont Pharmaceuticals Holdings, Inc. (“Rosemont”), a global specialty pharmaceutical company focused on designing and delivering medicines around patients' needs, today announced that it has entered into a definitive merger agreement to acquire Aytu BioPharma, Inc. (“Aytu”) (Nasdaq: AYTU), a US specialty pharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS) diseases.

Benchmark AYTU against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Aytu BioPharma, Inc. (AYTU)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.66 | $21.54M | -2.56 | -13.27% | -34.34% | -69.19% | — | |
| $29.04 | $3.54B | 7.87 | 4.29% | 32.75% | — | — | |
| $3.70 | $150.22M | 6.91 | 55.25% | 58.87% | 6.24% | 27.7% | |
| $15.76 | $2.18B | -1.24 | -2.75% | -43.27% | -68.13% | 7.3% | |
| $25.55 | $828.68M | 26.18 | 23.62% | 4.68% | 12.49% | — | |
| $240.71 | $15.12B | 75.62 | 4.88% | 4.37% | 4.62% | — |
Aytu BioPharma, Inc. (AYTU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Aytu BioPharma, Inc. (AYTU) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 13, 2026·SEC
Apr 2, 2026·SEC
Feb 3, 2026·SEC
Get notified when AYTU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Aytu BioPharma, Inc. (AYTU) stock FAQ — growth, dividends, profitability & financials explained
Aytu BioPharma, Inc. (AYTU) reported $58.5M in revenue over the trailing twelve months. Revenue was $57.6M in fiscal year 2026.
Aytu BioPharma, Inc. (AYTU) revenue fell by 8.1% over the trailing twelve months, compared with the twelve months before.
No. Aytu BioPharma, Inc. (AYTU) reported a net loss of $20.1M over the trailing twelve months.
Aytu BioPharma, Inc. (AYTU) had a return on equity (ROE) of -69.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
Aytu BioPharma, Inc. (AYTU) generated $3.6M in free cash flow over the trailing twelve months.